The AHA's statement addresses pediatric hypertriglyceridemia, affecting 10% to 20% of US children and adolescents.
Severe hypertriglyceridemia increases the risk of acute pancreatitis and atherosclerotic cardiovascular disease later in life.
Lifestyle modifications, including dietary changes and physical activity, are recommended as first-line therapy for managing hypertriglyceridemia.
No FDA-approved drugs exist for pediatric hypertriglyceridemia; pharmacotherapy may be considered for persistent high levels.
The statement emphasizes the need for further research on triglyceride-lowering therapies and lifestyle interventions in children.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
Editor
Affiliations:
Specialties:
Areas of Expertise:
